Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis

Background/Aim: There is no known report regarding the relationship of atezolizumab plus bevacizumab (Atez/Bev) treatment with muscle volume loss (MVL) in unresectable hepatocellular carcinoma (u-HCC) patients. This study aimed to elucidate the clinical relationship between MVL and Atez/Bev. Materials/Methods: From September 2020 to December 2021, 229 u-HCC patients treated with Atez/Bev and with muscle volume data obtained by computed tomography at the baseline available were analyzed (median age, 74 years; males, 186 (81.2%); ECOG PS 0/1, 221 (96.5%); HCV:HBV:alcohol:others = 81:33:40:75; Child-Pugh A, 212 (92.6%); modified albumin-bilirubin (mALBI) grade 1:2a:2b = 79:60:90; BCLC 0:A:B:C = 1:24:87:117; median observation period, 6.8 months). Japan Society of Hepatology criteria were used for definition of MVL and prognostic factors were retrospectively evaluated. Results: Multivariate Cox-hazard analysis of prognostic factors for progression-free survival (PFS) showed elevated alpha-fetoprotein (AFP) (≥100 ng/mL) (HR 1.848, 95% CI 1.264–2.702, p = 0.002), mALBI grade (≥2a) (HR 1.563, 95% CI 1.035–2.359, p = 0.034), and MVL (HR 1.479, 95% CI 1.020–2.144, p = 0.039) as significant factors. For overall survival (OS), significant factors included elevated AFP (≥100 ng/mL) (HR 3.564, 95% CI 1.856–6.844, p < 0.001), mALBI grade (≥2a) (HR 3.451, 95% CI 1.580–7.538, p = 0.002), and MVL (HR 2.119, 95% CI 1.150–3.904, p = 0.016). Patients with MVL (MVL group, n = 91) showed worse PFS than those without (non-MVL group, n = 138) (median PFS 5.3 vs. 7.6 months, p = 0.025), while the MVL group showed worse OS (p = 0.038), though neither reached the median survival time. Conclusion: MVL may be a clinical factor related to poor prognosis in patients receiving Atez/Bev treatment for u-HCC.

Angaben zum Objekt

• Standort: Deutsche Nationalbibliothek Frankfurt am Main
• Umfang: Online-Ressource
• Sprache: Englisch

Verweise und Beziehungen

• Erschienen in: Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis ; volume:12 ; number:3 ; year:2022 ; pages:209-217 ; extent:9 ; Liver cancer ; 12, Heft 3 (2022), 209-217 (gesamt 9)

Beteiligte, Orts- und Zeitangaben

• Urheber: Hiraoka, Atsushi ; Kumada, Takashi ; Tada, Toshifumi ; Hirooka, Masashi ; Kariyama, Kazuya ; Tani, Joji ; Atsukawa, Masanori ; Takaguchi, Koichi ; Itobayashi, Ei ; Fukunishi, Shinya ; Tsuji, Kunihiko ; Ishikawa, Toru ; Tajiri, Kazuto ; Ochi, Hironori ; Yasuda, Satoshi ; Toyoda, Hidenori ; Ogawa, Chikara ; Nishimura, Takashi ; Hatanaka, Takeshi ; Kakizaki, Satoru ; Shimada, Noritomo ; Kawata, Kazuhito ; Naganuma, Atsushi ; Kaibori, Masaki ; Tanaka, Takaaki ; Ohama, Hideko ; Nouso, Kazuhiro ; Morishita, Asahiro ; Tsutsui, Akemi ; Nagano, Takuya ; Itokawa, Norio ; Okubo, Tomomi ; Arai, Taeang ; Imai, Michitaka ; Koizumi, Yohei ; Nakamura, Shinichiro ; Joko, Kouji ; Iijima, Hiroko ; Kosaka, Hisashi ; Hiasa, Yoichi ; Kudo, Masatoshi

Weitere Informationen

• DOI: 10.1159/000527402
• URN: urn:nbn:de:101:1-2023081700284648171395
• Rechteinformation: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Letzte Aktualisierung: 14.08.2025, 10:57 MESZ